Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $205
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on AbbVie (NYSE:ABBV) and raises the price target from $200 to $205.
July 26, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on AbbVie and raises the price target from $200 to $205.
The raised price target and maintained Overweight rating from a reputable analyst at Wells Fargo is likely to positively impact AbbVie's stock price in the short term as it signals confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100